Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | NTRK2 positive |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| NTRK2 positive | pulmonary large cell neuroendocrine carcinoma | sensitive | AZD7451 | Preclinical | Actionable | In a preclinical study, AZD7451 treatment inhibited proliferation of a lung large-cell neuroendocrine carcinoma cell line expressing Ntrk2 in culture (PMID: 25054037). | 25054037 | |
| NTRK2 positive | neuroblastoma | sensitive | GNF-4256 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, GNF-4256 treatment inhibited BDNF-induced phosphorylation of Ntrk2 and growth of neuroblastoma cell lines expressing Ntrk2 in culture, and slowed tumor growth in the neuroblastoma cell line xenograft models (PMID: 25394774). | 25394774 | |
| NTRK2 positive | neuroblastoma | sensitive | GNF-4256 + Irinotecan + Temozolomide | Preclinical - Cell line xenograft | Actionable | In a preclinical study, GNF-4256 worked synergistically with Camptosar (irinotecan) and Temodar (temozolomide), resulting in growth inhibition and an increased event-free survival in cell line xenograft models of neuroblastoma expressing Ntrk2 (PMID: 25394774). | 25394774 |